Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1200

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 2
Chunk 1200
---
As of June 18, 2025, the Company
leased facilities for corporate and R&D purposes at locations throughout the United States and in various locations outside of the
United States. Our executive office is located at 900 Stewart Avenue, Suite 310, Garden City, NY 11530, and is under a lease that expires
in June 2031. We have an office in Dublin, Ireland under a lease that expires in September 2028 and an office space in Rehovot, Israel
under a lease that expires over the course of the next fiscal year. The Company has a research and development facility in Madison, Wisconsin
under a lease that expires in May 2026. The Company believes the existing facilities which are used by all reportable segments of the
Company and are in good operating condition and are suitable for the conduct of its business.

ITEM 3. LEGAL PROCEEDINGS

From time to time, the Company
is involved in various legal matters arising in the normal course of business. Litigation and other disputes are inherently unpredictable
and subject to substantial uncertainties and unfavorable resolutions could occur. At the same time, the Company does not expect the outcome
of such proceedings, either individually or in aggregate, to have a material effect on its financial position, cash flows or results of
operations.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

74

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY,
RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock has been listed
under the symbol “XAIR” on the Nasdaq Capital Market since May 7, 2019. From August 28, 2018 until May 6, 2019, our common
stock was quoted on the OTC Pink.

On June 18, 2025, the closing price for our common
stock as reported on The Nasdaq Capital Market was $0.2023 per share.

Stockholders

As of June 18, 2025, there were
approximately 97 holders of record for shares of our common stock. This does not reflect beneficial stockholders who held their common
stock in “street” or nominee name through brokerage firms.

Securities Authorized
for Issuance Under Equity Compensation Plans

Information regarding securities
authorized for issuance under our equity compensation plans is contained in Part III, Item 12 of this Annual